cMYC siRNA

cMYC siRNA refers to a research-stage class of small interfering RNA (siRNA) molecules designed to silence the expression of the c-MYC oncogene. c-MYC is a master transcription factor that regulates a vast network of genes involved in cell proliferation, growth, metabolism, and apoptosis, and its overexpression is a hallmark of many human cancers. These synthetic siRNA oligonucleotides function by utilizing the RNA interference (RNAi) pathway to target and promote the degradation of c-MYC mRNA, thereby preventing the translation of the c-MYC protein. Because c-MYC is traditionally considered undruggable by small molecules due to its lack of a defined ligand-binding pocket, siRNA-based approaches represent a promising therapeutic strategy. Various academic and research institutions, including the University of Puerto Rico and the University of North Carolina at Chapel Hill, have explored cMYC siRNA using advanced delivery vehicles like lipid nanoparticles (LNPs) or nanoliposomes to improve stability and cellular uptake in preclinical models of prostate cancer, ovarian cancer, and non-small-cell lung cancer (NSCLC).

Other names

c-MYC siRNAMYC siRNA